Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

MedTech

GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada GenePOC member of the Debiopharm, is proud to announce the approval by Health Canada and the launch of its GenePOC CDiff assay to be used with the revogene™ instrument.

Read more ...

Innovation unlocks previously inaccessible cellular information and makes more experiments feasible in proteogenomics, immune monitoring, and single-cell genomics. Celsee, launched its first product, the Genesis system, designed to overcome the limitations of other tools for single-cell analysis. The Genesis system provides a robust, scalable, and flexible way for scientists to analyze and interpret cellular behavior and collect critical cell-based information that was previously undetectable. Initial applications include proteogenomics; immune monitoring as an alternative to flow cytometry; and expansion and scale of next-generation sequencing library preparation.

Read more ...

In the last decade, MUT technologies have created a high level of excitement. Today, CMUT (capacitive micro-machined ultrasonic transducer), using capacitive properties, has pirevealed an excellent alternative to bulk piezoelectric modules for making products smaller, with a high level of integration, and at a lower cost. A number of applications are possible, from handheld non-destructive tests for industrial markets, to medical imaging. As described in Yole Développement (Yole)'s latest report, Ultrasound Sensing Technologies for Medical, Industrial, and Consumer Applications 2018, huge market opportunities in ultrasonic-based products for imaging applications are now available for CMUT to penetrate. This market’s total value is expected to reach $6B in 2023.

Read more ...

BGI Americas and Gencove announced that they have agreed to join their respective technologies into a single low-pass sequencing service. The service will join BGI's DNBseq next-generation sequencing technology — which uses combinatorial probe-anchor synthesis, rolling circle replication linear amplification, and DNA nanoballs — with Gencove's ImputeSeq low-pass sequencing analysis pipeline.

Read more ...

New assays empower clinicians to more quickly make the right diagnosis at the point-of-care and prescribe the right treatment. Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing1,2. These new assays enable the fastest-ever3 time to molecular influenza A & B and Strep A results at the point of care. Currently available on the ID NOW™ platform (formerly Alere i), both assays have been granted a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver.

Read more ...

Abbott announced that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.

Read more ...

Upcoming Events

No events

Presentation

Micromachined Ultrasound Technologies: An Overview of Emerging Trends and Applications
Discover the presentation held by Jérôme Mouly, Senior Technology & Market Analyst, Inkjet...
CRISPR Technology & Market Overview: challenges, market competition landscape and strategic opportunities
Discover the presentation held by Asma Siari, Technology & Market Analyst in Biotechnologies...
Birth of a Future Giant: Zoom on the Chinese Microfluidics Industry
Discover the presentation held by Sébastien Clerc, Market & Technology Analyst, Microfluidi...

Access to all our presentations